|
Market Closed -
NSE India S.E.
04:35:10 17/11/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 1,870.00 INR | +0.13% |
|
-1.81% | +8.74% |
| 04/11 | India proposes instant manufacturing licence suspension for drugs failing quality tests | RE |
| 02/11 | Indian shares set for positive start on talks to end Iran war, strong Reliance earnings | RE |
| Market Cap | 4,48700Cr 4.8TCr 4.36TCr 4.03TCr 3.63TCr 6.86TCr 7.12TCr 49TCr 19TCr 2,42100Cr 18TCr 18TCr 7,64900Cr | P/E 2027 * |
36.5x | P/E 2028 * | 30x |
|---|---|---|---|---|---|
| Enterprise Value | 4,19100Cr 4.49TCr 4.07TCr 3.76TCr 3.39TCr 6.41TCr 6.65TCr 45TCr 18TCr 2,26100Cr 17TCr 16TCr 7,14500Cr | EV / Sales 2027 * |
6.47x | EV / Sales 2028 * | 5.7x |
| Free-Float |
44.39% | Yield 2027 * |
0.88% | Yield 2028 * | 1.05% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| SUNPHARMA | Delayed | |
| 524715 | Delayed |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.13% | ||
| 1 week | -1.81% | ||
| Current month | +5.19% | ||
| 1 month | +6.32% | ||
| 3 months | -0.64% | ||
| 6 months | -0.44% | ||
| Current year | +8.74% |
| 1 week | 1,856.8 | 1,915 | |
| 1 month | 1,719.1 | 1,943.9 | |
| Current year | 1,583.7 | 2,046.9 | |
| 1 year | 1,583.7 | 2,046.9 | |
| 3 years | 1,184.5 | 2,046.9 | |
| 5 years | 733.7 | 2,046.9 | |
| 10 years | 312 | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 59 | 01/09/2025 | |
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 71 | 21/05/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.13% | -1.81% | +6.02% | +56.54% | 4.77TCr | ||
| -1.13% | -1.17% | +38.55% | +139.23% | 1,27500Cr | ||
| -1.36% | -0.74% | +39.64% | +86.06% | 68TCr | ||
| -0.59% | -0.36% | +25.14% | +111.73% | 52TCr | ||
| -0.76% | +1.10% | +41.43% | +70.96% | 39TCr | ||
| -0.75% | -3.16% | +54.39% | +40.90% | 36TCr | ||
| -1.83% | -0.89% | +26.00% | +58.48% | 31TCr | ||
| -1.65% | -0.59% | +1.55% | +34.52% | 29TCr | ||
| -0.95% | -1.57% | +34.01% | +72.55% | 25TCr | ||
| +1.60% | -0.36% | +37.21% | +125.66% | 21TCr | ||
| Average | -0.73% | -0.52% | +30.39% | +79.66% | 43TCr | |
| Weighted average by Cap. | -0.96% | -0.56% | +34.64% | +95.19% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 65TCr 693.61Cr 629.66Cr 581.65Cr 524.74Cr 990.63Cr 1.03TCr 7.01TCr 2.77TCr 35TCr 2.6TCr 2.55TCr 1,10500Cr | 72TCr 774.19Cr 702.81Cr 649.23Cr 585.7Cr 1.11TCr 1.15TCr 7.82TCr 3.09TCr 39TCr 2.9TCr 2.84TCr 1,23300Cr |
| Net income | 12TCr 129.25Cr 117.33Cr 108.39Cr 98Cr 184.6Cr 191.66Cr 1.31TCr 516.57Cr 6.52TCr 484.93Cr 474.72Cr 21TCr | 15TCr 160.71Cr 145.9Cr 134.77Cr 121.59Cr 229.54Cr 238.32Cr 1.62TCr 642.33Cr 8.1TCr 602.98Cr 590.29Cr 26TCr |
| Net Debt | -30TCr -316.78Cr -287.57Cr -265.65Cr -239.65Cr -452.43Cr -469.75Cr -3.2TCr -1.27TCr -16TCr -1.19TCr -1.16TCr -50TCr | -37TCr -392.23Cr -356.07Cr -328.92Cr -296.73Cr -560.19Cr -581.64Cr -3.96TCr -1.57TCr -20TCr -1.47TCr -1.44TCr -62TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/26/17 | ₹1,870.00 | +0.13% | 14,38,065 |
| 16/26/16 | ₹1,867.50 | -0.66% | 13,01,410 |
| 13/26/13 | ₹1,880.00 | -0.27% | 20,37,762 |
| 12/26/12 | ₹1,885.00 | -0.91% | 24,64,003 |
| 11/26/11 | ₹1,902.30 | -0.12% | 22,62,492 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions

















